HIGHLIGHTS
- who: Shibin Zhu from the Hospital de Sabadell, Spain have published the paper: Case report: Significant benefits of tislelizumab combined with anlotinib in first-line treatment of metastatic renal pelvic urothelial carcinoma with sarcomatoid carcinoma differentiation, in the Journal: (JOURNAL) of 20,/01/2021
- future: More research is needed to understand this rare malignant tumor to optimize current treatments. survival outcomes were observed in TKI/ICI combination group with ORR rates of 50-60% and a median OS of over 20 months.
SUMMARY
UTUC is a rare type of tumors originated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.